molsidomine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1831	25717-80-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

molsidomine
molsidolat
morsydomine
motazomin
molsidomin

A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.

Molecular weight: 242.24
Formula: C9H14N4O4
CLOGP: 0.56
LIPINSKI: 0
HAC: 8
HDO: 0
TPSA: 72.60
ALOGS: -1.88
ROTB: 4

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	48 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	162.61	51.40	49	1633	25285	63462055
Antinuclear antibody negative	86.48	51.40	13	1669	221	63487119
Dermatitis exfoliative	83.82	51.40	21	1661	5438	63481902
Coombs positive haemolytic anaemia	80.50	51.40	13	1669	358	63486982
Antiphospholipid syndrome	77.26	51.40	16	1666	1774	63485566
Hyperthyroidism	71.39	51.40	23	1659	14650	63472690
Cholecystitis	70.33	51.40	23	1659	15354	63471986
Herpes simplex reactivation	68.24	51.40	12	1670	556	63486784
Respiratory disorder	65.58	51.40	28	1654	39054	63448286
Electrolyte imbalance	64.32	51.40	23	1659	20053	63467287
Gastritis haemorrhagic	61.98	51.40	13	1669	1532	63485808
Complex regional pain syndrome	56.51	51.40	13	1669	2344	63484996
Multiple organ dysfunction syndrome	55.60	51.40	28	1654	56724	63430616
Product prescribing error	54.79	51.40	22	1660	26267	63461073

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	68.68	37.38	49	1310	128220	34827352
Pyelitis	44.34	37.38	7	1352	111	34955461
Dizziness	39.02	37.38	45	1314	218476	34737096

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	121.83	34.13	48	2547	44533	79697260
Product prescribing error	87.61	34.13	38	2557	44775	79697018
Electrolyte imbalance	69.67	34.13	29	2566	30852	79710941
Dermatitis exfoliative	65.27	34.13	21	2574	10808	79730985
General physical health deterioration	61.67	34.13	59	2536	275179	79466614
Hyperthyroidism	57.40	34.13	23	2572	22186	79719607
Respiratory disorder	56.31	34.13	28	2567	44828	79696965
Cholecystitis	53.96	34.13	22	2573	22190	79719603
Fall	44.43	34.13	66	2529	487563	79254230
Syncope	39.21	34.13	38	2557	179411	79562382
Mucosal erosion	38.97	34.13	10	2585	2308	79739485
Pyelitis	38.11	34.13	7	2588	336	79741457
Cholelithiasis	35.95	34.13	22	2573	52642	79689151
Dyspnoea	34.90	34.13	82	2513	856943	78884850

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Small for dates baby	17.17	17.12	7	4	2802	86979

Pharmacologic Action:

Source	Code	Description
ATC	C01DX12	CARDIOVASCULAR SYSTEM CARDIAC THERAPY VASODILATORS USED IN CARDIAC DISEASES Other vasodilators used in cardiac diseases
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D020030	Nitric Oxide Donors
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:50566	nitric oxide generators
CHEBI has role	CHEBI:68494	apoptosis inhibitors
CHEBI has role	CHEBI:77307	cardioprotective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Angina pectoris	indication	194828000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.48	acidic
pKa2	6.72	Basic
pKa3	1.29	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN		IC50	4.61		CHEMBL

External reference:

ID	Source
N0000167103	NUI
D01320	KEGG_DRUG
C0026400	UMLSCUI
CHEBI:31861	CHEBI
CHEMBL1329455	ChEMBL_ID
CHEMBL1256353	ChEMBL_ID
DB09282	DRUGBANK_ID
D008981	MESH_DESCRIPTOR_UI
5353788	PUBCHEM_CID
3125	INN_ID
D46583G77X	UNII
7023	RXNORM
005842	NDDF
698196008	SNOMEDCT_US

Pharmaceutical products:

None